Join Clinical Trials in Colorado for Allergies

All Categories Medical Conditions » Allergies » Colorado

Identification of Molecular Biomarkers to Stratify Patients With Refractory Asthma

Condition: Asthma
Intervention:
Sponsors: National Jewish Health; National Jewish Health; MedImmune LLC
Recruiting - verified April 2012
A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

Condition: Asthma
Interventions: Drug: MEMP1972A; Drug: MEMP1972A; Drug: MEMP1972A; Drug: placebo
Sponsors: Genentech; Genentech
Not yet recruiting - verified April 2012
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting - verified May 2012
A Study of ARRY-502 in Patients With Persistent Asthma

Condition: Asthma
Interventions: Drug: ARRY-502, CRTh2 antagonist; oral; Drug: Placebo; oral
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified May 2012
A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients

Condition: Asthma
Interventions: Drug: ONO-6950; Drug: ONO-6950; Drug: Montelukast; Drug: Placebo
Sponsors: Ono Pharma; Ono Pharma; Ono Pharmaceutical Co. Ltd
Recruiting - verified March 2012
ADRN Influenza Vaccine Pilot

Condition: Atopic Dermatitis
Intervention: Drug: Fluzone® Intradermal (Sanofi Pasteur Inc.)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified May 2012
Safety Study in Adolescent and Adult Patients With Asthma

Condition: Asthma
Interventions: Drug: Placebo; Drug: Primatene Mist; Drug: Epinephrine inhalation aerosol, HFA; Drug: epinephrine inhalation aerosol
Sponsors: Amphastar Pharmaceuticals, Inc.; Amphastar Pharmaceuticals, Inc.
Recruiting - verified November 2011
Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma

Condition: Asthma
Intervention: Drug: VR506
Sponsors: Vectura Limited; Vectura Limited
Recruiting - verified November 2011
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)

Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012
Registry for the Atopic Dermatitis Research Network

Conditions: Atopic Dermatitis; Eczema Herpeticum
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)

Condition: Seasonal Allergic Rhinitis
Interventions: Drug: Ciclesonide nasal aerosol 37 mcg; Drug: ciclesonide nasal aerosol 74 mcg; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012
Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy

Condition: Peanut Allergy
Interventions: Drug: QGE031; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).

Conditions: Perennial Allergic Rhinitis; PAR
Interventions: Drug: Ciclesonide nasal aerosol 37 mcg; Drug: ciclesonide nasal aerosol 74 mcg; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified March 2012
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012
A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise

Condition: Activity/Exercise Induced Bronchospasm
Interventions: Drug: Fluticasone Furoate/Vilanterol Inhalation Powder; Drug: Fluticasone Propionate Inhalation Powder
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified October 2011
Dose Finding Study for QAW039 in Asthma

Condition: Asthma
Interventions: Drug: QAW039; Drug: Comparator leukotriene receptor antagonist (LRTA); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations

Condition: Asthma
Interventions: Biological: Omalizumab; Drug: Fluticasone; Other: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012
A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma

Condition: Asthma
Intervention: Drug: Tralokinumab
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified January 2012
Interferon Responses in Eczema Herpeticum (ADEH)

Conditions: Atopic Dermatitis; Eczema Herpeticum; Herpes Simplex Infections; Eczema Vaccinatum
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Jewish Health; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2011
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

Condition: Hereditary Angioedema
Intervention: Drug: icatibant
Sponsors: Shire Human Genetic Therapies, Inc.; Shire Human Genetic Therapies, Inc.
Recruiting - verified May 2012
Asthma Phenotypes in the Inner City

Condition: Asthma
Intervention: Drug: Flovent Diskus, Advair Diskus, Ventolin HFA, cetirizine, Flonase Nasal Spray, Singulair
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011
Eosinophilic Esophagitis Databank

Conditions: Esophagitis; Eosinophilic Esophagitis
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2012
Efficacy, Safety, and Tolerability of SAR231893(REGN668) in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Condition: Asthma
Interventions: Biological: SAR231893 (REGN668); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified April 2012
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 Years of Age) With Eosinophilic Asthma

Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Placebo
Sponsors: Cephalon; Cephalon
Recruiting - verified April 2012
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Placebo
Sponsors: Cephalon; Cephalon
Recruiting - verified April 2012
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Reslizumab; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified April 2012
Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma

Condition: Asthma
Interventions: Drug: Vitamin D3; Drug: Ciclesonide
Sponsors: Milton S. Hershey Medical Center; Milton S. Hershey Medical Center; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2012
A Non-drug Study Profiling Asthma

Conditions: Asthma; Health
Intervention: Other: All patients
Sponsors: Centocor, Inc.; Centocor, Inc.
Recruiting - verified April 2012
A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo

Condition: Asthma
Interventions: Drug: budesonide; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012
Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

Condition: Asthma
Interventions: Drug: fluticasone propionate and salmeterol; Drug: budesonide and formoterol
Sponsors: National Jewish Health; National Jewish Health
Recruiting - verified July 2011
Study of Asthma and Nasal Steroids

Conditions: Asthma; Rhinitis; Sinusitis
Interventions: Drug: Mometasone Furoate monohydrate; Other: Placebo
Sponsors: American Lung Association Asthma Clinical Research Centers; American Lung Association Asthma Clinical Research Centers; National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2011
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

Condition: Hereditary Angioedema
Intervention: Biological: Cinryze
Sponsors: ViroPharma; ViroPharma
Recruiting - verified April 2011
Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index

Conditions: Deglutition Disorders; Esophageal Diseases; Eosinophilia
Intervention: Other: assessment of disease activity using the EEsAI
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne; Institute of Social and Preventive Medicine, University Bern; Dept. of Gastroenterology, Kantonsspital Olten, Olten; Luzerner Kantonsspital; Mayo Clinic Rochester, Minnesota, USA; University of Cincinnati; University of Colorado, Denver; Northwestern University of Chicago, Illinois, USA; Indiana University School of Medicine; Philadelphia University
Recruiting - verified March 2012
A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

Condition: Asthma
Interventions: Drug: Levalbuterol; Drug: Levalbuterol UDV TID; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified February 2012
A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis

Condition: Atopic Dermatitis
Intervention:
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012